NO20082072L - Dihydrogen fosfatsalt av en prostaglandin D2 reseptorantagonist - Google Patents

Dihydrogen fosfatsalt av en prostaglandin D2 reseptorantagonist

Info

Publication number: NO20082072L
Authority: NO; Norway
Prior art keywords: iii; formula; diseases; dihydrogen phosphate; urticaria
Prior art date: 2005-10-13

Application number

NO20082072A

Other languages

English (en)

Norwegian (no)

Inventor

Beverly Langevin

Edward Orton

Daniel Sherer

Original Assignee

Aventis Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-13

Filing date

2008-05-02

Publication date

2008-05-02

2008-05-02 Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc

2008-05-02 Publication of NO20082072L publication Critical patent/NO20082072L/no

Links

NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 title abstract 2
229940122913 Prostaglandin D2 receptor antagonist Drugs 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
206010012438 Dermatitis atopic Diseases 0.000 abstract 2
206010061218 Inflammation Diseases 0.000 abstract 2
208000003251 Pruritus Diseases 0.000 abstract 2
208000024780 Urticaria Diseases 0.000 abstract 2
208000026935 allergic disease Diseases 0.000 abstract 2
201000008937 atopic dermatitis Diseases 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
230000004054 inflammatory process Effects 0.000 abstract 2
230000007803 itching Effects 0.000 abstract 2
FJKKCRCBBAXLQZ-UHFFFAOYSA-N 2-[3-[6-[2-(2,4-dichlorophenyl)ethylamino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropanoic acid Chemical compound C=1C(C=2C=C(C=CC=2)C(C)(C)C(O)=O)=NC(OC)=NC=1NCCC1=CC=C(Cl)C=C1Cl FJKKCRCBBAXLQZ-UHFFFAOYSA-N 0.000 abstract 1
206010002198 Anaphylactic reaction Diseases 0.000 abstract 1
206010006482 Bronchospasm Diseases 0.000 abstract 1
208000002177 Cataract Diseases 0.000 abstract 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
206010009900 Colitis ulcerative Diseases 0.000 abstract 1
206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
201000004624 Dermatitis Diseases 0.000 abstract 1
102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 abstract 1
101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 abstract 1
206010020751 Hypersensitivity Diseases 0.000 abstract 1
206010063837 Reperfusion injury Diseases 0.000 abstract 1
206010038848 Retinal detachment Diseases 0.000 abstract 1
206010039085 Rhinitis allergic Diseases 0.000 abstract 1
201000008736 Systemic mastocytosis Diseases 0.000 abstract 1
201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
201000010105 allergic rhinitis Diseases 0.000 abstract 1
230000007815 allergy Effects 0.000 abstract 1
230000036783 anaphylactic response Effects 0.000 abstract 1
208000003455 anaphylaxis Diseases 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
208000010668 atopic eczema Diseases 0.000 abstract 1
238000010009 beating Methods 0.000 abstract 1
206010006451 bronchitis Diseases 0.000 abstract 1
230000007885 bronchoconstriction Effects 0.000 abstract 1
230000020411 cell activation Effects 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
210000003630 histaminocyte Anatomy 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
230000000302 ischemic effect Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
235000016709 nutrition Nutrition 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
208000008423 pleurisy Diseases 0.000 abstract 1
BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 abstract 1
BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 abstract 1
230000004264 retinal detachment Effects 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
238000007790 scraping Methods 0.000 abstract 1
230000035939 shock Effects 0.000 abstract 1
208000019116 sleep disease Diseases 0.000 abstract 1
230000009885 systemic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20082072A 2005-10-13 2008-05-02 Dihydrogen fosfatsalt av en prostaglandin D2 reseptorantagonist NO20082072L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72629005P	2005-10-13	2005-10-13
PCT/US2006/039901 WO2007047378A2 (en)	2005-10-13	2006-10-12	Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist

Publications (1)

Publication Number	Publication Date
NO20082072L true NO20082072L (no)	2008-05-02

Family

ID=37963090

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20082072A NO20082072L (no)	2005-10-13	2008-05-02	Dihydrogen fosfatsalt av en prostaglandin D2 reseptorantagonist

Country Status (35)

Country	Link
US (1)	US7642249B2 (sr)
EP (1)	EP1948620B1 (sr)
JP (1)	JP2009511591A (sr)
KR (1)	KR101365480B1 (sr)
CN (1)	CN101287714B (sr)
AR (1)	AR058085A1 (sr)
AU (1)	AU2006304187B2 (sr)
BR (1)	BRPI0617311A2 (sr)
CA (1)	CA2625563C (sr)
CR (1)	CR9870A (sr)
DK (1)	DK1948620T3 (sr)
DO (2)	DOP2006000223A (sr)
EC (1)	ECSP088362A (sr)
ES (1)	ES2409833T3 (sr)
GT (1)	GT200600457A (sr)
HN (1)	HN2008000603A (sr)
HR (1)	HRP20130341T1 (sr)
IL (1)	IL190673A (sr)
MA (1)	MA30005B1 (sr)
MY (1)	MY145648A (sr)
NI (1)	NI200800116A (sr)
NO (1)	NO20082072L (sr)
NZ (1)	NZ567433A (sr)
PE (1)	PE20070791A1 (sr)
PL (1)	PL1948620T3 (sr)
PT (1)	PT1948620E (sr)
RS (1)	RS52799B (sr)
RU (1)	RU2419614C2 (sr)
SI (1)	SI1948620T1 (sr)
TN (1)	TNSN08131A1 (sr)
TW (1)	TW200728288A (sr)
UA (1)	UA93062C2 (sr)
UY (1)	UY29862A1 (sr)
WO (1)	WO2007047378A2 (sr)
ZA (1)	ZA200802586B (sr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GT200500284A (es) *	2004-10-15	2006-03-27	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2
DOP2007000068A (es) *	2006-04-12	2007-10-31	Sanofi Aventis Us Llc	Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
WO2007146838A2 (en) *	2006-06-09	2007-12-21	Icos Corporation	Substituted phenyl acetic acids as dp-2 antagonists
EP2170837B1 (en) *	2007-06-29	2011-11-02	Sanofi	Process for preparing 2-(3-{6-[2-(2,4-dichlorophenyl)-ethylamino]-2-methoxypyrimidin-4-yl)-phenyl)-2-methylpropionic acid
BRPI0907364A2 (pt)	2008-02-01	2015-07-14	Amira Pharmaceuticals Inc	Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
JP2011513242A (ja)	2008-02-25	2011-04-28	アミラファーマシューティカルズ，インク．	プロスタグランジンｄ２受容体アンタゴニスト
GB2463788B (en) *	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en)	2008-10-01	2010-04-08	Amira Pharmaceuticals, Inc.	Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en)	2008-10-08	2010-04-15	Amira Pharmaceuticals, Inc.	Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
WO2010045633A2 (en) *	2008-10-17	2010-04-22	National Jewish Health	Measurement and analysis of leukotrienes
AR074776A1 (es) *	2008-12-18	2011-02-09	Sanofi Aventis	Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
EP2461809A4 (en)	2009-07-31	2013-06-19	Panmira Pharmaceuticals Llc	OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
US8815917B2 (en)	2009-08-05	2014-08-26	Panmira Pharmaceuticals, Llc	DP2 antagonist and uses thereof
WO2012004800A1 (en)	2010-07-08	2012-01-12	Ramot At Tel-Aviv University Ltd.	Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions
WO2012044561A2 (en) *	2010-09-30	2012-04-05	Merck Sharp & Dohme Corp.	2-alkoxy pyrimidine pde10 inhibitors
ES2690782T3 (es)	2012-10-24	2018-11-22	Nyu Winthrop Hospital	Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro
JP6770522B2 (ja)	2015-02-13	2020-10-14	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
SI3302448T1 (sl)	2015-06-04	2024-03-29	Aurigene Oncology Limited	Substituirani heterociklični derivati kot inhibitorji cdk
CA3075688A1 (en)	2017-09-13	2019-03-21	Progenity, Inc.	Preeclampsia biomarkers and related systems and methods
EP4070113A4 (en)	2019-12-04	2023-12-20	Biora Therapeutics, Inc.	ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4711888A (en) *	1985-07-24	1987-12-08	Pfizer Inc.	Hydroxy and alkoxy pyrimidines
ATE466581T1 (de) *	2001-12-07	2010-05-15	Vertex Pharma	Verbindungen auf pyrimidin-basis als gsk-3-hemmer
MXPA06000269A (es) *	2003-07-09	2006-04-07	Hoffmann La Roche	Tiofenilaminoimidazolinas.
GT200500284A (es) *	2004-10-15	2006-03-27	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2

2006
- 2006-10-11 GT GT200600457A patent/GT200600457A/es unknown
- 2006-10-12 JP JP2008535672A patent/JP2009511591A/ja not_active Abandoned
- 2006-10-12 PL PL06825836T patent/PL1948620T3/pl unknown
- 2006-10-12 PT PT68258367T patent/PT1948620E/pt unknown
- 2006-10-12 RS RS20130225A patent/RS52799B/sr unknown
- 2006-10-12 MY MYPI20081085A patent/MY145648A/en unknown
- 2006-10-12 UA UAA200806196A patent/UA93062C2/ru unknown
- 2006-10-12 PE PE2006001242A patent/PE20070791A1/es not_active Application Discontinuation
- 2006-10-12 SI SI200631572T patent/SI1948620T1/sl unknown
- 2006-10-12 ES ES06825836T patent/ES2409833T3/es active Active
- 2006-10-12 BR BRPI0617311-0A patent/BRPI0617311A2/pt not_active IP Right Cessation
- 2006-10-12 RU RU2008118491/04A patent/RU2419614C2/ru not_active IP Right Cessation
- 2006-10-12 AU AU2006304187A patent/AU2006304187B2/en not_active Ceased
- 2006-10-12 NZ NZ567433A patent/NZ567433A/en not_active IP Right Cessation
- 2006-10-12 EP EP06825836A patent/EP1948620B1/en active Active
- 2006-10-12 HR HRP20130341TT patent/HRP20130341T1/hr unknown
- 2006-10-12 CA CA2625563A patent/CA2625563C/en not_active Expired - Fee Related
- 2006-10-12 AR ARP060104475A patent/AR058085A1/es not_active Application Discontinuation
- 2006-10-12 KR KR1020087008805A patent/KR101365480B1/ko not_active Expired - Fee Related
- 2006-10-12 WO PCT/US2006/039901 patent/WO2007047378A2/en not_active Ceased
- 2006-10-12 DK DK06825836.7T patent/DK1948620T3/da active
- 2006-10-12 CN CN2006800378860A patent/CN101287714B/zh not_active Expired - Fee Related
- 2006-10-13 UY UY29862A patent/UY29862A1/es unknown
- 2006-10-13 DO DO2006P000223A patent/DOP2006000223A/es unknown
- 2006-10-13 TW TW095137635A patent/TW200728288A/zh unknown
- 2006-10-13 DO DO2006000220A patent/DOP2006000220A/es unknown
2008
- 2008-03-19 TN TNP2008000131A patent/TNSN08131A1/en unknown
- 2008-03-20 ZA ZA200802586A patent/ZA200802586B/xx unknown
- 2008-04-07 IL IL190673A patent/IL190673A/en not_active IP Right Cessation
- 2008-04-07 CR CR9870A patent/CR9870A/es not_active Application Discontinuation
- 2008-04-10 EC EC2008008362A patent/ECSP088362A/es unknown
- 2008-04-11 NI NI200800116A patent/NI200800116A/es unknown
- 2008-04-11 HN HN2008000603A patent/HN2008000603A/es unknown
- 2008-04-11 US US12/101,282 patent/US7642249B2/en not_active Expired - Fee Related
- 2008-05-02 MA MA30890A patent/MA30005B1/fr unknown
- 2008-05-02 NO NO20082072A patent/NO20082072L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2625563A1 (en)	2007-04-26
ECSP088362A (es)	2008-05-30
ZA200802586B (en)	2009-09-30
RU2419614C2 (ru)	2011-05-27
RS52799B (sr)	2013-10-31
US7642249B2 (en)	2010-01-05
HRP20130341T1 (en)	2013-05-31
DOP2006000220A (es)	2007-05-15
TNSN08131A1 (en)	2009-07-14
UY29862A1 (es)	2007-05-31
WO2007047378A3 (en)	2007-08-02
PL1948620T3 (pl)	2013-08-30
CA2625563C (en)	2011-04-19
BRPI0617311A2 (pt)	2011-07-19
EP1948620A2 (en)	2008-07-30
WO2007047378A2 (en)	2007-04-26
AR058085A1 (es)	2008-01-23
AU2006304187A1 (en)	2007-04-26
CN101287714A (zh)	2008-10-15
IL190673A (en)	2011-12-29
AU2006304187B2 (en)	2011-04-28
JP2009511591A (ja)	2009-03-19
SI1948620T1 (sl)	2013-05-31
KR101365480B1 (ko)	2014-02-21
PE20070791A1 (es)	2007-08-16
EP1948620B1 (en)	2013-03-20
ES2409833T3 (es)	2013-06-28
GT200600457A (es)	2007-04-27
RU2008118491A (ru)	2009-11-20
UA93062C2 (ru)	2011-01-10
ES2409833T8 (es)	2013-09-26
NI200800116A (es)	2011-12-15
IL190673A0 (en)	2008-11-03
MA30005B1 (fr)	2008-12-01
MY145648A (en)	2012-03-15
KR20080057275A (ko)	2008-06-24
US20080194600A1 (en)	2008-08-14
DK1948620T3 (da)	2013-06-24
NZ567433A (en)	2010-06-25
DOP2006000223A (es)	2007-05-15
CR9870A (es)	2008-06-18
HN2008000603A (es)	2010-11-03
PT1948620E (pt)	2013-05-06
TW200728288A (en)	2007-08-01
HK1125133A1 (en)	2009-07-31
CN101287714B (zh)	2011-04-06

Legal Events

Date	Code	Title	Description
2015-05-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20082072L (no)	2008-05-02	Dihydrogen fosfatsalt av en prostaglandin D2 reseptorantagonist
UA88485C2 (en)	2009-10-26	2,6-substituted-4-monosubstituted amino-pyrimidines as prostaglandin d2 receptor antagonists
NO20090862L (no)	2009-02-24	2-fenyl-indoler som prostaglandin D2-reseptorantagonister
TNSN08339A1 (en)	2009-12-29	2,6 -substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists
TNSN07251A1 (en)	2008-12-31	2-phenyl-indoles as prostaglandin d2 receptor antagonists
BRPI0511344A (pt)	2007-12-04	composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto combinado
NO20076450L (no)	2008-02-15	Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi
EP1262475A4 (en)	2005-01-05	INDOIND DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
NO20071988L (no)	2007-04-18	Kjemiske forbindelser
MA29231B1 (fr)	2008-02-01	Nouveaux composes heterocycliques utiles pour le traitement de troubles inflammatoires et allergiques
MX2011004553A (es)	2011-07-20	Piridina, piridina biciclica y analogos relacionados como moduladores de sirtuina.
NO20073436L (no)	2007-09-05	Nye heterosykliske forbindelser nyttige for behandling av inflammatoriske og allergiske forstyrrelser
EP1666473A4 (en)	2009-06-03	CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENT
TW200635932A (en)	2006-10-16	New pyridothienopyrimidine derivatives
WO2007062318A3 (en)	2008-01-17	Chemical compounds
Srinath et al.	2011	Anti-hyperlipidemic activity of thieno-[2, 3-d]-pyrimidin-4-(3H)-ones
TH106955A (th)	2011-03-30	2-เฟนิล-อินโดล ที่เป็นกลุ่มสารต้านตัวรับพรอสตาแกลนดิน d2
Rangappa Srinath et al.	2011	Anti-hyperlipidemic activity of thieno-[2, 3-d]-pyrimidin-4-(3H)-ones.
TH87151A (th)	2007-10-19	สารประกอบเคมี